drugset / Trial / NCT02221258
Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of phase 1 clinical trial is to to evaluate safety in subjects with moderate to severe rheumatoid arthritis after infusion.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FURESTEM-RA Inj | Cell therapy | 2.5e+07 cells | Other |
| Subject | FURESTEM-RA Inj | Cell therapy | 5e+07 cells | Other |
| Subject | FURESTEM-RA Inj | Cell therapy | 1e+08 cells | Other |